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ABSTRACT 
Neuroendocrine Neoplasms (NENs) of the Gastrointestinal Tract (GIT) are a 
heterogeneous group of tumours with varied biologic potential and clinical outcomes.  
They are classified as well differentiated neuroendocrine tumours (WD NET) or poorly 
differentiated neuroendocrine carcinomas (PD NECs) based on morphology.  WD NETs are 
further subtyped (grade 1, 2 or 3) by evaluating the mitotic rate and Ki-67 proliferative 
index.  The most recent grading system was published in 2019 by the World Health 
Organisation (WHO).  Insulinoma-associated protein 1 (INSM1) is a transcription factor 
that is expressed in neuroendocrine cells, and recent studies have shown that it is a 
sensitive and specific marker for neuroendocrine differentiation.  
The aims of this study were to grade NENs of the GIT according to the 2019 WHO grading 
system, and to evaluate the expression of INSM1 in order to assess its sensitivity and 
specificity as a marker of neuroendocrine differentiation compared to chromogranin A 
(CgA) and synaptophysin (SYN). 
Sixty-nine GIT NENs diagnosed between 2003 and 2017 at Groote Schuur Hospital were 
included in this study.  The mitotic rate and Ki-67 proliferation index were evaluated for 
each case.  We identified 38 grade 1 NETs, 16 grade 2 NETs, 1 grade 3 NET, 13 small cell 
type NECs and 1 large cell type NEC.  INSM1 immunohistochemical staining was 
performed on all cases.  To assess specificity, we evaluated the expression of INSM1 in 
other GIT primary tumours (adenocarcinoma, gastrointestinal stromal tumour, lymphoma, 
leiomyoma and Kaposi sarcoma).  Eighty percent of our NEN cases stained with INSM1. 
We found the sensitivity of INSM1 to be higher than CgA (68%), but lower than SYN (87%) 
and the combined use of CgA-SYN (94%) when considering all NENs.  When evaluating 
only the PD NEC cases, INSM1 had a higher sensitivity than CgA (50%) and SYN (64%), and 
an equal sensitivity to the combined use of CgA-SYN (79%). 
v 
We conclude that the high sensitivity and specificity of INSM1 make it a valuable 
standalone marker for assessing neuroendocrine differentiation.  The nuclear reactivity 
and high sensitivity of INSM1 make it the preferred neuroendocrine marker for PD NEC. 
vi 
TABLE OF CONTENTS 
DECLARATION ............................................................................................................... ii 
ACKNOWLEDGEMENTS ................................................................................................ iii 
ABSTRACT .....................................................................................................................iv 
LIST OF TABLES .............................................................................................................. ix 
LIST OF FIGURES ............................................................................................................ x 
LIST OF ABBREVIATIONS ................................................................................................ xi 
1. INTRODUCTION AND LITERATURE REVIEW ................................................................ 1 
1.1 Introduction ................................................................................................................. 1 
1.2 Historical perspective ................................................................................................... 2 
1.3 Epidemiology ................................................................................................................ 3 
1.3.1 Incidence  ............................................................................................................... 3 
1.3.2 Geographic distribution ......................................................................................... 4 
1.3.3 Age ......................................................................................................................... 4 
1.3.4 Gender ................................................................................................................... 4 
1.4 Aetiopathogenesis........................................................................................................ 5 
1.5 Clinical features ............................................................................................................ 5 
1.6 Pathology...................................................................................................................... 6 
1.6.1 Macroscopic pathology ......................................................................................... 6 
1.6.2 Microscopic pathology .......................................................................................... 6 
1.6.3 World Health Organization (WHO) Grading system ............................................. 7 
1.6.3.1 Mitotic count .................................................................................................. 8 
1.6.3.2 Ki-67 proliferative index ................................................................................. 8 
vii 
1.7 Immunohistochemistry ................................................................................................ 9 
1.7.1 INSM1 .................................................................................................................... 9 
1.7.2 Chromogranin A................................................................................................... 10 
1.7.3 Synaptophysin ..................................................................................................... 10 
1.7.4 Ki-67 ..................................................................................................................... 10 
1.8 Study design ............................................................................................................... 11 
1.8.1 Study aims ........................................................................................................... 11 
1.8.2 Study objectives ................................................................................................... 11 
2. MATERIAL AND METHODS ....................................................................................... 13 
2.1 Ethics approval ........................................................................................................... 13 
2.2 Acquisition of cases .................................................................................................... 13 
2.3 Acquisition of controls ............................................................................................... 15 
2.4 Antibodies .................................................................................................................. 15 
2.5 Immunohistochemistry .............................................................................................. 16 
2.6 Haematoxylin and Eosin method ............................................................................... 17 
2.7 Interpretation of immunohistochemical staining ...................................................... 18 
2.8 Tumour morphology .................................................................................................. 18 
2.9 Grading of tumours .................................................................................................... 19 
2.10 Site of tumours ......................................................................................................... 20 
2.11 Statistical analysis .................................................................................................... 21 
3. RESULTS .................................................................................................................. 22 
3.1 Cases and Controls ..................................................................................................... 22 
3.2 Age .............................................................................................................................. 24 
3.3 Gender ........................................................................................................................ 25 
viii 
3.4 Type of sample ........................................................................................................... 26 
3.5 Site of tumour ............................................................................................................ 26 
3.6 Grading ....................................................................................................................... 27 
3.7 Immunohistochemistry .............................................................................................. 34 
3.7.1 INSM1 .................................................................................................................. 34 
3.7.2 Synaptophysin ..................................................................................................... 36 
3.7.3 Chromogranin A................................................................................................... 38 
3.8 Sensitivity and Specificity of Immunohistochemical Stains ....................................... 40 
4. DISCUSSION ............................................................................................................ 45 
4.1 Age .............................................................................................................................. 45 
4.2 Gender ........................................................................................................................ 45 
4.3 Type of sample ........................................................................................................... 45 
4.4 Site of tumour ............................................................................................................ 46 
4.5 Grading ....................................................................................................................... 46 
4.6 Immunohistochemistry .............................................................................................. 47 
4.6.1 INSM1 .................................................................................................................. 47 
4.6.2 Synaptophysin ..................................................................................................... 48 
4.6.3 Chromogranin A................................................................................................... 48 
4.7 Comparison of INSM1, Synaptophysin and Chromogranin A .................................... 49 
4.8 Study design ............................................................................................................... 50 
5. CONCLUSIONS ......................................................................................................... 52 
6. APPENDICES ............................................................................................................ 53 
7. REFERENCES ............................................................................................................ 57 
ix 
LIST OF TABLES 
Table 1: The 2019 WHO classification of GI NENs ................................................................. 8 
Table 2: Primary antibody information ............................................................................... 15 
Table 3: Kits used in this study............................................................................................. 17 
Table 4: Intensity and proportion values required to meet the H-score cut-off ................ 18 
Table 5: Controls stratified by anatomic site and diagnosis ................................................ 23 
Table 6: Comparison of age (years) between tumour groups ............................................. 24 
Table 7: Mean age at diagnosis of NENs grouped by anatomic site ................................... 24 
Table 8: Comparison of gender between tumour groups ................................................... 25 
Table 9: Gender composition of NENs grouped by anatomic site ...................................... 25 
Table 10: Comparison of specimen type (biopsy/excision) and NEN group ....................... 26 
Table 11: Number of tumours graded according to 2019 WHO classification system ....... 29 
Table 12: Comparison of the NEN grades found at different anatomical sites ................... 33 
Table 13: INSM1 staining stratified by tumour grade and anatomic site............................ 36 
Table 14: Synaptophysin staining stratified by tumour grade and anatomic site ............... 38 
Table 15: Chromogranin A staining stratified by tumour grade and anatomic site ............ 40 
Table 16: Cases positive for different numbers of immunohistochemical markers ........... 40 
Table 17: Sensitivities and specificities of IHC markers based on tumour type and grade 41 
x 
LIST OF FIGURES 
Figure 1: Diagrammatic representation of the case recruitment process .......................... 22 
Figure 2: Proportion of study cases illustrated according to anatomical site ..................... 27 
Figure 3: Examples of Ki-67 manual counting technique (400x magnification) .................. 28 
Figure 4: WD NET (NEN_03) low magnification showing insular growth (H&E, 40x).......... 29 
Figure 5: WD NET (NEN_03) high magnification showing round nuclei with stippled 
chromatin (H&E, 400x) ........................................................................................................ 30 
Figure 6: PD NEC small cell type (NEN_02) showing sheets of tumour cells, intermediate 
magnification (H&E, 100x) ................................................................................................... 30 
Figure 7: PD NEC small cell type (NEN_02) showing round to polyhedral cells with scanty 
cytoplasm and high nuclear-to-cytoplasmic ratios, high magnification (H&E, 400x) ......... 31 
Figure 8: PD NEC large cell type (NEN_45) showing medium sized cells with basophilic 
cytoplasm and large ovoid nuclei, high magnification (H&E, 400x) .................................... 31 
Figure 9: WD NET grade 3 (NEN_32) showing nests of tumour cells underlying a mucosal 
ulcer, intermediate magnification (H&E, 100x) ................................................................... 32 
Figure 10: WD NET grade 3 (NEN_32) showing tumour cells with moderate eosinophilic 
cytoplasm and nuclei with stippled chromatin, high magnification (H&E, 400x) ............... 33 
Figure 11: Staining intensities of INSM1 (400x magnification) ........................................... 35 
Figure 12: Staining intensities of synaptophysin (400x magnification) ............................... 37 
Figure 13: Staining intensities of chromogranin A (400x magnification) ............................ 39 
Figure 14: ROC curve considering all cases of NEN ............................................................. 42 
Figure 15: ROC curve considering only PD NEC cases ......................................................... 43 
Figure 16: ROC curve evaluating only the grade 1 WD NET cases ...................................... 44 
Figure 17: ROC curve evaluating only the grade 2 WD NET cases ...................................... 44 
xi 
LIST OF ABBREVIATIONS 
AJCC - American Joint Committee on Cancer
APUD - Amine precursor uptake and decarboxylation
AUC - Area under curve
CgA - Chromogranin A
EC - Enterochromaffin
ECL - Enterochromaffin-like cell
GI - Gastrointestinal
GIT - Gastrointestinal tract
GIST - Gastrointestinal stromal tumour
H&E - Haematoxylin and Eosin
HIAA - Hydroxyindoleacetic acid
IHC - Immunohistochemistry
INSM1 - Insulinoma-associated protein 1
LIS - Laboratory information system
MEN - Multiple endocrine neoplasia
MiNEN  - Mixed neuroendocrine-non-neuroendocrine neoplasms
NEC - Neuroendocrine carcinoma
NEN - Neuroendocrine neoplasm
NET - Neuroendocrine tumour
NF1 - Neurofibromatosis type 1
PanNET - Pancreatic neuroendocrine tumour
PBS - Phosphate buffered saline
PD - Poorly differentiated
ROC - Receiver operating characteristic
SEER - Surveillance epidemiology and end results
SYN - Synaptophysin
WD - Well differentiated
xii 
WHO - World Health Organisation
1 
1. INTRODUCTION AND LITERATURE REVIEW
1.1 Introduction 
Neuroendocrine neoplasms (NENs) occur in epithelial organs throughout the body where 
they demonstrate a wide variety of clinical presentations, morphological features, genetic 
findings, and outcomes. 
In 2018, the WHO published a uniform classification schema for NENs which separates 
them into two distinct morphologic groups: well differentiated neuroendocrine tumours 
(WD NETs) and poorly differentiated neuroendocrine carcinomas (PD NECs).(1)  
Morphologic features and proliferation rates are used to distinguish these.  This 
distinction is supported by clinical, epidemiological, genetic and prognostic differences.  
The recently published 2019 WHO classification of tumours of the digestive system has 
adopted this framework for the classification of gastrointestinal (GI) NENs.(2) 
Neuroendocrine lineage is proven by immunohistochemistry.  The traditional 
neuroendocrine immunohistochemical markers have varying sensitivities and specificities 
depending on the grade and anatomic site of the tumour.  There is interest in a novel 
neuroendocrine transcription factor Insulinoma-associated protein 1 (INSM1) which has 
shown promising results in the lung, head and neck and skin.  The utility of this marker in 
the digestive tract has only recently been reported, long after the current study protocol 
was finalised.(3) 
The prevalence of NENs in South Africa is not well documented, and the frequency at 
which the different tumour grades occurs is also not known.  The role of INSM1 in 
demonstrating neuroendocrine differentiation in GI NENs has similarly not been 
investigated in the South African context.  
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1.2 Historical perspective 
Siegfried Oberndorfer was the first to recognize the difference between malignant 
epithelial tumours of the terminal ileum (carcinomas) and a group of more benign-
behaving lesions which he termed carcinoid tumours.(4)  Since his original description of 
“karzinoides” in 1907, NEN terminology and classification has undergone several 
revisions. 
Oberndorfer first described carcinoids in the terminal ileum as multiple superficial 
tumourlets with an indolent behaviour.  Years later, he recognised that some carcinoids 
behaved in a malignant manner and were able to metastasize.  In 1963, Williams and 
Sandler proposed classifying WD NETs based on their embryological origin.(5)  Tumours 
were thus grouped as foregut (lung, thymus, stomach, duodenum, pancreas, proximal 
jejunum), midgut (distal jejunum, ileum, appendix, caecum) and hindgut (colon and 
rectum) tumours.  In 1966, Pearse recognised the biochemical characteristics of 
neuroendocrine cells and proposed the term APUD (amine precursor uptake and 
decarboxylation).(6)  For a time the term “apudoma” prevailed in the literature. 
In the 1980 WHO classification the term carcinoid applied to all tumours derived from the 
diffuse neuroendocrine system.  These were then subclassified based on silver and other 
staining characteristics into enterochromaffin (EC) cell carcinoids, gastrin cell carcinoids 
and other carcinoids. 
Carcinoid is a historic term that is widely prevalent in the literature.  However, it does not 
sufficiently convey the heterogeneity in behaviour and outcomes of WD NETs.  This was 
recognised in the early 1990s, and in 2000 the WHO eliminated the term carcinoid from 
their classification system.  This classification grouped tumours by anatomic site and 
recognised the importance of prognostic groups.(7, 8)  However, terminology was still 
confusing and the distinction between NET and NEC was based on the presence of 
metastases in the latter. 
3 
The distinction between WD NETs and PD NECs was recognised in the 2010 WHO 
classification system.  This distinction was based on morphology, mitotic rate and the Ki-
67 proliferative index.  It is now appreciated that WD NETs are distinct from conventional 
adenocarcinomas with neuroendocrine differentiation and PD NECs.  NECs develop from a 
surface epithelial precursor and are closely related to conventional adenocarcinomas.  
WD NETs develop from cells of the diffuse neuroendocrine cell system.  This distinction is 
important as there are marked differences in clinical presentation and prognosis between 
the two groups. 
The 2019 WHO classification of digestive system tumours further emphasizes the 
importance of morphology in separating the NETs from NECs.  The concept of a grade 3 
WD NET has been introduced, which has the same cut off values for mitotic count and Ki-
67 index as PD NEC, but resembles a WD NET morphologically and behaves in a less 
aggressive manner than PD NEC.(2) 
1.3 Epidemiology 
1.3.1 Incidence  
The Surveillance Epidemiology and End Results (SEER) database provides the most 
comprehensive data on the incidence of GI NENs in the United States.   
Small intestinal NENs are reported in the literature with an annual incidence of 1.2 cases 
per 100000 and account for approximately 27% of GI NENs.(9-11)  Appendiceal NENs 
occur in the general population at a rate of 0.15 to 0.6 per 100 000 annually.(11)   Colonic 
NENs are the least common GI NEN and occur with an annual incidence of 0.2 per 100 
000.(11)  Many of these tumours occur in the caecum and it has been suggested that 
there may be overlap with appendiceal and ileal NENs, and that true colonic NENs are 
even rarer than this data suggests.  The annual incidence of rectal NENs is the highest in 
the GIT at 1.2 per 100 000.(11)  The incidence of gastric NENs has increased over the past 
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decade due to increasing use of upper endoscopy.  The estimated annual incidence of 
gastric NENs in the USA and Europe is approximately 0.4 cases per 100 000.(11, 12)  
Gastric NECs account for 21% of all gastric NENs and approximately 20.5% of all GIT 
NECs.(13) 
To our knowledge, there is no data on the incidence of GI NENs in South Africa. 
1.3.2 Geographic distribution 
Rectal NETs occur most frequently among the Asian-Pacific Island, American-Indian and 
African-American populations, compared to Caucasians.(2)  Colonic NETs are more 
common in Caucasians.  NENs of the stomach, small bowel and appendix show no 
geographic predilection. 
1.3.3 Age 
GI NENs are predominantly tumours of adulthood and occur only rarely in children.  The 
mean age at diagnosis for small intestinal NENs is 65 years.(9)  NENs of the stomach 
present at a mean age of 64 years.  Rectal NENs occur in a younger age group and are 
diagnosed at a mean age of 57 years.  For colonic NENs the mean age is 64 years.  The 
highest incidence of appendiceal NENs is before the age of 40 years with a mean age at 
presentation of 33.2 years.(14, 15) 
1.3.4 Gender 
The prevalence for gastric, small intestinal, colonic and rectal NENs is similar amongst 




GI NENs occur sporadically for the most part, although they may rarely occur in 
association with familial endocrine syndromes with germline mutations.  These tumours 
are generally localized to the duodenum and may be seen in association with multiple 
endocrine neoplasia type 1 (MEN1) and neurofibromatosis type 1 (NF1).  The aetiology 
and pathogenesis of the sporadic small intestinal NENs is unknown.   
Gastric type 1 ECL-cell WD NETs are the most common (80-90%) gastric NET and are 
associated with autoimmune gastritis.  Type 2 ECL-cell WD NETs are seen in association 
with gastrinomas in the context of MEN1.  The pathogenesis of both type 1 and type 2 
ECL-cell WD NETs is related to unregulated gastrin stimulation of ECL cells.(16)  There are 
no specific aetiologic factors for type 3 gastric WD NETs and PD NECs, and the 
pathogenesis of both is unknown. 
The aetiology and pathogenesis of appendiceal and colorectal NENs is unknown.(2)  A 
recent meta-analysis of colorectal NENs showed an increased risk with alcohol 
consumption.(17) 
1.5 Clinical features 
Jejunoileal NENs may present with bowel obstruction, ischaemia or intussusception.(18)  
Up to 75% of patients with small intestinal NENs present with liver metastases, and at the 
time of diagnosis the primary intestinal NEN has usually not been identified.  Intestinal 
NENs may be functional and produce a variety of hormones.  The most common and well-
known are serotonin and other vasoactive substances which, when released from liver 
metastases, can cause the carcinoid syndrome.  Carcinoid syndrome manifests as episodic 
flushing of the face and neck, sweating, diarrhoea, wheezing and heart disease.(19)   
6 
Duodenal NENs are more likely to be functional.  Patients with incidentally detected NENs 
are usually asymptomatic.  They may have elevated serum chromogranin A and urine 5- 
hydroxyindoleacetic acid (HIAA) or even liver metastases.(18) 
The majority of appendiceal NENs occur in the tip of the organ, are clinically silent, and 
are discovered incidentally.(18)  Up to 10% of cases can occur more proximally and may 
present as acute appendicitis. 
Rectal NENs are mostly small (<1cm) and detected incidentally on routine colonoscopy.  
Larger rectal NENs may cause mucosal ulceration and rectal bleeding. 
Most patients with gastric NEN are asymptomatic.  The commonest clinical sign at 
presentation is anaemia; symptoms such as dyspepsia, vomiting and abdominal pain may 
also occur. 
1.6 Pathology 
1.6.1 Macroscopic pathology 
Small intestinal, colonic and rectal NETs generally appear as small firm nodules or 
polypoid submucosal lesions without mucosal involvement.  Jejunoileal NETs may be 
multifocal in up to a third of cases.(20)  On cut surface they are white to yellow in colour. 
Mesenteric involvement is common.   
1.6.2 Microscopic pathology 
WD NETs show a variety of growth patterns which are related to the cell of origin and the 
peptide secretory product.  The classic jejunoileal WD NETs which are thought to derive 
from serotonin expressing EC-cells are also the commonest type found in the colon and 
appendix.  They show well-defined nests with solid, insular, and acinar growth.  
Appendiceal WD NETs with this morphology are unique in that the nests are often 
surrounded by S100 positive spindled cells.(21)  WD NETs derived from L-cells producing 
7 
glucagon-like peptides and peptide YY are typically found in the rectum and are the 
second most common architectural pattern in the appendix.  Chromogranin A 
immunohistochemical staining is known to be variable in tumours derived from L-
cells.(18)  WD NETs derived from L-cells show trabecular and ribbon-like growth within 
abundant collagen-rich stroma.  Appendiceal WD NETs can show a tubular growth pattern 
(least common) which needs to be distinguished from goblet cell carcinoids and 
adenocarcinomas. 
The cells comprising WD NETs contain eosinophilic cytoplasmic secretory granules which 
are accentuated at the periphery of the cell nests.  The cells are evenly spaced and there 
is minimal cytonuclear pleomorphism.  Nuclei are round to ovoid in shape with stippled 
chromatin.  Both perineural and lymphovascular invasion are commonly observed. 
PD NECs show a solid growth pattern composed of sheets or nests of cells.  Trabecular 
growth is less common.(22)  The neoplastic cells in small cell PD NEC vary from round to 
polyhedral to spindled and have scanty cytoplasm with high nuclear-to-cytoplasmic ratios. 
Nuclear molding is commonly observed.  Mitoses and apoptosis are conspicuous.  
Necrosis is frequently seen.   
The clinical significance of the histologic subclassification into small cell and large cell 
groups has not been established.(18)  Large cell PD NECs are defined by the presence of 
large polyhedral cells with moderate basophilic cytoplasm, and enlarged vesicular nuclei 
with prominent nucleoli.  They are prone to form organoid structures with scattered 
rosettes and pseudorosettes.(22) 
1.6.3 World Health Organization (WHO) Grading system 
The 2019 WHO classification of tumours of the digestive system has separated WD NETs 
from PD NECs based on tumour morphology, mitotic count and Ki-67 proliferative index. 
We have chosen to use this grading schema for the purposes of our study (Table 1). 
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Table 1: The 2019 WHO classification of GI NENs 
Mitotic count (per 
2mm2) 
Ki-67 proliferative index 
Well differentiated NET 
 Grade 1 < 2 < 3% 
 Grade 2 2 – 20 3 – 20% 
 Grade 3 > 20 > 20%
Poorly differentiated NEC 
 Small cell type > 20 > 20%
 Large cell type > 20 > 20%
1.6.3.1 Mitotic count 
Mitotic rates are to be expressed as the number of mitoses per 2mm2.  This area equates 
to 10 high-power fields at 400x magnification when using a microscope with an ocular 
field diameter of 0.5mm.  Most modern microscopes have a wider field diameter and this 
needs to be considered when determining how many high-power fields should be 
counted.  It is currently recommended to count mitoses in an area of 10mm2 and then 
report the rate as per 2mm2.  These recommendations are endorsed by the WHO, 
American Joint Committee on Cancer (AJCC) and College of American Pathologists.(2, 23) 
1.6.3.2 Ki-67 proliferative index 
The Ki-67 proliferative index is determined by identifying the region of highest 
immunolabelling (hotspot) and counting at least 500 cells in this region.  There is no 
universally accepted technique for performing this count.  Most experts advocate a 
manual count which can be done digitally or on a printed photomicrograph.(24)  Another 
acceptable technique is using digital software packages which perform automated cell 
counting.  This has limitations which include the software’s inability to detect overlapping 
cells, staining of non-tumour cells and background brown pigment like haemosiderin.  
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Estimating the Ki-67 index by the “eyeball” technique is controversial as studies have 
shown different interobserver variabilities.(25-27)  Eyeballing is now discouraged due to 
challenges with interobserver variability.(26) 
1.7 Immunohistochemistry 
1.7.1 INSM1 
Insulinoma-associated protein 1 (INSM1) is a zinc-finger transcription factor which was 
initially described in pancreatic insulinomas.(28)  Subsequently, it has been found to be 
central to early neuroendocrine differentiation in developing embryonal tissues, and is 
directly responsible for the transcription of synaptophysin and chromogranin A.(29)  The 
INSM1 gene is located on chromosome 20p11.23. 
INSM1 is the only commercially available neuroendocrine marker for diagnostic 
immunohistochemistry that shows nuclear localisation.  This is advantageous particularly 
in the evaluation of small cell PD NECs where minimal cytoplasm is present to stain for the 
traditional neuroendocrine markers, chromogranin A and synaptophysin.  In the past 
three years INSM1 has emerged as a reliable marker in the identification of NENs.(30)  
Studies have established its role as a sensitive and specific immunohistochemical marker 
in thoracic NENs, head and neck NENs and Merkel cell carcinoma.(31-35)  
Recently, a study by Gonzalez et al. evaluated the sensitivity and specificity of INSM1 in a 
series of 30 gastroenteropancreatic-NENs.(3)  They found a sensitivity of 100% and a 
specificity of 96%.  There was only one NEC (1/30) in this study. 
INSM1 has not been evaluated in the South African context. 
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1.7.2 Chromogranin A 
Chromogranin A is an acidic protein which belongs to a family of granins present in the 
secretory granules of neuroendocrine cells and tumours.(36)  Chromogranin A has been 
studied extensively in human tumours and it is present in most NENs.  Granins are located 
primarily in secretory granules within the cytoplasm, and thus immunolabelling may be 
reduced in tumours which have minimal cytoplasm such as small cell NECs.(37, 38) 
Chromogranin A immunohistochemistry is typically strongly positive in well to moderately 
differentiated NETs, whereas it is only focally positive or lost in PD NECs.(39, 40)  The 
sensitivity of chromogranin A in detecting NENs in the left colon and rectum is 20-
50%.(41) 
1.7.3 Synaptophysin 
Synaptophysin is a 38-kDa transmembrane glycoprotein found in the membranes of 
presynaptic vesicles in neurons and neuroendocrine cells.(38)  These cytoplasmic vesicles 
are different from the granules in which chromogranin is found and therefore the staining 
pattern is different.(38)  Synaptophysin is not specific for GI NENs and also stains other 
tumours showing neuroendocrine differentiation such as paragangliomas, 
phaeochromocytomas and medullary thyroid carcinomas.  Adrenocortical adenomas and 
carcinomas typically also label with synaptophysin. 
Synaptophysin is considered the most sensitive marker for neuroendocrine differentiation 
in the GIT.(42)  However, it is not entirely specific and its combined use with 
chromogranin A is recommended.(43)  Synaptophysin is cited as being positive in only 
approximately 50% of gastric NETs.(18, 22)  
1.7.4 Ki-67 
The Ki-67 antibody recognizes a nuclear protein expressed by actively dividing cells in the 
G1, G2, S and M phases of the cell cycle.  This protein is not found in cells in the resting 
(G0) phase.  The Ki-67 proliferative index is a frequently reported parameter in a variety of 
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neoplasms and is central (together with the mitotic rate) to the classification and grading 
of NENs.  Increased ischaemic time, from vascular clamping and resection to formalin 
fixation, significantly decreases the number of mitotic figures.(44)  Therefore the Ki-67 is 
often higher than the mitotic rate and determines the NEN grade.(42)  Evaluation of the 
Ki-67 index may be influenced by the antibody clone, different staining protocols, tissue 
section thickness and density of tumour cells.(42) 
The protein recognised by the Ki-67 antibody can be detected by immunohistochemical 
staining with the MIB-1 monoclonal antibody.  Strong dark brown granular nuclear 
staining is interpreted as positive.(45) 
1.8 Study design 
1.8.1 Study aims 
The aims of this study were as follows: 
1. To describe the epidemiological features of GI NENs seen in the Division of
Anatomical Pathology at Groote Schuur Hospital from 2003 - 2017.
2. To reclassify the NENs according to the latest (2019) WHO criteria.
3. To determine the sensitivity and specificity of the immunohistochemical stain
(INSM1) in the South African setting and compare it to chromogranin A and
synaptophysin.
1.8.2 Study objectives 
Reclassification of the NENs seen in the Division of Anatomical Pathology at Groote 
Schuur Hospital from 2003 - 2017 according to the latest (2019) WHO grading system. 
This will be achieved by performing a formal mitotic count and evaluation of the Ki-67 
proliferative index. 
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Comparison of the sensitivity and specificity of the new neuroendocrine 
immunohistochemical marker INSM1 to that of the traditional markers, synaptophysin 
and chromogranin A.  This will be done in order to determine whether INSM1 can be used 
to replace the combination of synaptophysin and chromogranin A as a panel for 
neuroendocrine differentiation. 
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2. MATERIAL AND METHODS
2.1 Ethics approval 
Ethics approval for this study was obtained from the University of Cape Town Faculty of 
Health Sciences Human Research Ethics Committee (Reference number: 176/2018).  
Scientific approval for this MMed study was obtained from the Department of Pathology 
Research Committee. 
Funding for this study was obtained from the National Health Laboratory Service (NHLS) 
Research Trust Development Grant (Reference number: 2018-1DEV21-MLO01). 
This was a retrospective study performed on archival material, and patient management 
was not directly affected in any way.  The patient’s data was anonymised and each 
specimen was allocated a study number.  The data was stored in an electronic password 
protected document.  The physical materials for the study (glass slides, wax blocks) were 
stored in a locked cupboard in a locked office with electronic access control to the 
department. 
2.2 Acquisition of cases 
This was a retrospective study.  Cases of GI NENs (both biopsy and resection specimens) 
seen in the Division of Anatomical Pathology, National Health Laboratory Service - Groote 
Schuur Hospital were examined.  The study period included cases from 2003 to 2017. 
We searched the Disa and Trakcare laboratory information systems (LISs) using the terms 
“carcinoid tumour”, “neuroendocrine tumour”, “neuroendocrine carcinoma”, “small cell 
carcinoma”, and “large cell neuroendocrine carcinoma”.  The study was limited to the GI 
tract from the stomach to the rectum and excluded pancreatic NENs.  Five primary 
anatomic sites of interest were identified: stomach, small intestine, appendix, colon and 
rectum.  Liver metastases with no identifiable primary tumour were excluded.  Goblet cell 
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carcinoids and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) were also 
excluded. 
The database search returned 236 cases (134 excision specimens and 102 biopsies).  We 
prioritised the excision specimens during the case selection, as they had more tissue 
available for further stains.  Fifty-nine of the 134 excision specimens were 
appendicectomy cases (44%).  We included 25 appendicectomy cases, and all the excision 
specimens that were from sites other than the appendix.  The remaining cases were made 
up of biopsies to bring the total from each anatomic site to 25 cases.  When selecting the 
appendicectomy cases and the biopsies, we prioritised the more recent cases as these 
were felt to be more suitable for antigen retrieval.  We excluded biopsies that had a 
follow up excision specimen from the selection. 
We anticipated that not all cases would be suitable for inclusion (due to inaccessible or 
lost tissue blocks, poorly preserved tissue blocks and cases with small tumour volumes not 
amenable to further sectioning) and were aiming for 100 study cases. 
The slides of the selected cases were retrieved from the archives of the Division of 
Anatomical Pathology, National Health Laboratory Service – Groote Schuur hospital.  The 
slides were reviewed and a block was selected for immunohistochemistry.  The formalin 
fixed paraffin wax embedded tissue blocks were then retrieved from the archive. 
The age, gender, anatomic site and whether an excision or biopsy was performed was 
recorded from the Disa and Trakcare LISs.  It was noted whether synaptophysin, 
chromogranin A and Ki-67 immunostains were done on the cases, and these original slides 
were reviewed for possible inclusion in the study.  We performed immunohistochemistry 
for these markers on the cases for which we could not retrieve the slides, the slides were 
damaged, faded or uninterpretable, or where the markers were not done in the first 
instance. 
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2.3 Acquisition of controls 
We searched the Trakcare LIS to identify 4 non-NENs from each of the 5 anatomic sites 
selected for the study.  Resection specimens were identified.  The terms 
“adenocarcinoma”, “lymphoma”, “gastrointestinal stromal tumour”, “leiomyoma” and 
“Kaposi sarcoma” were searched to identify a variety of tumours frequently encountered 
at these sites. 
2.4 Antibodies 
The primary antibodies used were INSM1, synaptophysin, chromogranin A and Ki-67 
(Table 2).  A negative reagent control in which the primary antibody was replaced with 
PBS was used together with a positive tissue control for each IHC run. 


































Abbreviations: RT, room temperature; mono, monoclonal. 
Supplier information: 
Dako – Denmark 
Santa Cruz – Europe 
Novocastra – Leica, United Kingdom 
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2.5 Immunohistochemistry 
Immunohistochemistry was performed on sections cut from the formalin fixed paraffin 
embedded wax blocks according to the following protocol: 
1. Three-micron thick paraffin wax embedded tissue sections were cut, picked up
onto Histobond slides (Marienfeld-Germany) and heat fixed on a hotplate for 10-
15 min.
2. Sections were dewaxed through xylene, cleared in ethanol and rehydrated in
water.
3. Endogenous peroxidase activity was blocked by treating the slides with a 3%
hydrogen peroxide (H2O2) solution for 10 minutes.
4. Slides were washed well in water.
5. Antigen retrieval was performed by pressure-cooking slides in Tris EDTA (TEDTA)
or Citric acid (Table 2) for 1 minute 30 seconds at full pressure.
6. This was followed by washing in tap water.
7. Thereafter, slides were rinsed with phosphate buffered saline solution (PBS pH
7.6), (Oxoid-Hampshire, England).
8. Non-specific binding was blocked by treating slides with a 5% Goat Serum Solution
(DAKO- Denmark).
9. Serum was then drained off and sections were incubated with primary antibody at
room temperature at specified times and dilutions (Table 2).
10. The slides were then washed well with PBS solution.
11. This was followed by incubation with the (Monoclonal) DAKO Envision labelled
Polymer, HRP (DAKO- USA) (Table 3) for 30 minutes at room temperature.
12. Sections were washed well with PBS solution.
13. Positivity was developed by applying the chromogenic substrate 3,3 –
diaminobenzidine (DAB), (DAKO- USA) for 5-10 minutes.
14. Slides were washed in running tap water and counterstained with Mayers
haematoxylin for approximately 3 minutes.
15. After washing in running tap water, sections were blued in ammoniated water.
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16. Finally, the slides were dehydrated through alcohols, cleared with xylene and
mounted with Entellan, (MERCK- Germany).
Table 3: Kits used in this study 
Kit Supplier 
Envision HRP System Labelled Polymer Anti-
mouse 
Dako - CA, USA 
Liquid DAB + Substrate chromogen system Dako - CA, USA 
2.6 Haematoxylin and Eosin method 
Cases in which the retrieved H&E stained glass slides were unsuitable for evaluation were 
recut from the wax blocks and stained according to the following protocol: 
MAYERS HAEMATOXYLIN AND EOSIN METHOD: 
1. Sections were dewaxed in xylene, brought down through alcohols and washed well
in running tap water.
2. The slides were then stained in Mayers haematoxylin for 5 mins
3. Tissue sections were washed well in tap water and the nuclei blued with
ammoniated water.  The slides were washed again in tap water.
4. The cytoplasm and surrounding tissue were stained with 1% phloxine/eosin for 2
mins.
5. Slides were washed well in water, dehydrated in alcohol and cleared in xylene.
6. Finally, sections were mounted onto coverslips using Entellan.
Results: 
Nuclei - blue 
Cytoplasm and surrounding tissue - varying shades of pink. 
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2.7 Interpretation of immunohistochemical staining 
Assessment of positivity was determined by granular cytoplasmic staining for 
synaptophysin and chromogranin A, and nuclear staining for INSM1.  The intensity of 
staining and the proportion of tumour cells which stained positively was recorded.  The 
intensity was scored out of 3 (corresponding to mild, moderate, and strong), and the 
proportion was recorded as a percentage of the total number of tumour cells present in 
the section. 
The intensity score and proportion of positively staining cells were multiplied to produce a 
score out of 300 (H-score).  For the purposes of this study we regarded positivity to be an 
H-score of 30 or more out of 300. The minimum proportion of cells required for each
intensity score is shown in Table 4. 
Table 4: Intensity and proportion values required to meet the H-score cut-off 
Intensity Proportion H-score
1 30% 30 
2 15% 30 
3 10% 30 
Nuclear staining of tumour cells was assessed to determine the Ki-67 proliferative index, 
and this was expressed as a percentage of the total number of tumour cell nuclei present 
in the field of interest. 
2.8 Tumour morphology 
H&E stained sections were reviewed by light microscopy for all cases to confirm the 
diagnosis.  The distinction between well differentiated and poorly differentiated NENs was 
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made on light microscopy based on established morphologic criteria.  Small cell NEC and 
large cell NEC were also distinguished based on morphology.   
The following cytological features were used, in addition to the characteristic architectural 
growth patterns, to distinguish WD NET, small cell PD NEC and large cell PD NEC: 
WD NET: 
1. Medium sized cells with a low nuclear-to-cytoplasmic ratios.
2. Abundant cytoplasm.
3. Small round to ovoid nucleus
4. Dispersed chromatin containing small nucleoli.
PD NEC, small cell type: 
1. Small to medium sized cells with high nuclear-to-cytoplasmic ratios.
2. Scant basophilic cytoplasm.
3. Elongated nuclei.
4. Finely dispersed chromatin without nucleoli.
PD NEC, large cell type: 
1. Medium to large sized cells.
2. Basophilic cytoplasm.
3. Large ovoid nuclei.
4. Large nucleoli.
2.9 Grading of tumours 
We performed a formal mitotic count on H&E stained sections by identifying the area of 
the tumour with the most mitotic activity on scanning magnification (the so-called hot 
spot).  The number of mitotic figures was then counted in an area of 10mm2 (42 
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consecutive high-power fields based on the field diameter of my microscope, 0.55 mm).  
The mitotic rate was then reported as per 2mm2 which is the current recommendation by 
the WHO.  To be as accurate as possible, we did not round off the mitotic rate to achieve 
a whole number of mitoses.  For example: 11 mitoses counted in 42 high power fields was 
reported as 2.2 mitoses per 2mm2.  
The Ki-67 proliferative index was determined be identifying the area with the highest 
number of positively staining tumour cells on scanning magnification (hot spot).  This area 
was photographed at high magnification (400x).  Using the Microsoft Paint software 
program (Washington, USA), a red dot was placed over all the nuclei which showed 
positive labelling with the Ki-67 immunostain.  Black dots were placed over the 
haematoxylin-stained tumor cell nuclei which did not label with the Ki-67 antibody until a 
total of 500 cells had been counted.  Care was taken to only include tumour cells in this 
count, and lymphocytes, endothelial cell and fibroblasts were excluded.  The Ki-67 
proliferative index was expressed as a percentage. 
For the purposes of this study we used the 2019 WHO 5th edition classification schema for 
grading neuroendocrine neoplasms of the digestive system (Table 1).  In cases where 
there was discrepancy between the Ki-67 proliferative index and the mitotic count we 
assigned the higher tumour grade. 
2.10 Site of tumours 
The site of the tumours was obtained from the Disa and Trakcare LISs.  The anatomic site 
was grouped as stomach, small intestine, appendix, colon or rectum.  The site was 
confirmed histologically by examination of the H&E stained sections. 
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2.11 Statistical analysis 
Categorical variables were compared in contingency tables using the Fisher’s exact test 
and Chi squared test.  Student’s t-test was used for hypothesis testing when comparing 
two sample means.  Statistical analysis and interpretation were performed using the IBM 
SPSS Statistics software package (New York, USA).  Results were considered statistically 
significant if p < 0.05. 
Sensitivity was defined as the ability of the immunohistochemical stain (INSM1, 
chromogranin A, synaptophysin) to correctly identify NENs (true positives).  This was 
calculated by dividing the number of cases that were positive for the 
immunohistochemical stain by the total number of NEN cases. 
Specificity was defined as the ability of the immunohistochemical stain (INSM1, 
chromogranin A, synaptophysin) to correctly identify the non-NEN controls (true 
negatives).  This was calculated by dividing the number of controls that were negative for 
the immunohistochemical stain by the total number of controls.   
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3. RESULTS
3.1 Cases and Controls 
Sixty-nine cases were retrieved from the archives that had enough remaining tissue in the 
wax block and were suitable for analysis (Figure 1). 
Figure 1: Diagrammatic representation of the case recruitment process
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Seventeen tissue control blocks were retrieved from the archives.  These specimens 
originated from a spectrum of anatomic sites and represented a variety of tumour types 
found in the GIT (Table 5). 
Table 5: Controls stratified by anatomic site and diagnosis 
Number 
Stomach 
 Adenocarcinoma 3 
 GIST 2 
Small intestine 
 Lymphoma 3 
 GIST 2 
 Leiomyoma 1 
Appendix 
 Kaposi sarcoma 2 
 Lymphoma 1 
Colorectum 
 Adenocarcinoma 3 
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3.2 Age 
Age was available for all cases on the electronic database.  The age range for all the cases 
was 14-85 years with a mean age of 56,7 years (Table 6).  WD NETs had a significantly 
lower mean age of 53,4 (range 14-76 years), compared to the PD NECs (mean 70 years; 
range 51-85) (t= -3.95, p <0.001).  Mean age grouped by anatomic site is shown below in 
Table 7.   
Table 6: Comparison of age (years) between tumour groups 
All cases WD NET PD NEC 
Number of cases 69 55 14 
Age range (years) 14-85 14-76 51-85
Mean age (years) 56.7 53.4 70 
Student T-test p < 0.001 
Table 7: Mean age at diagnosis of NENs grouped by anatomic site 
NEN mean age 
(years) 
WD NET mean age 
(years) 
PD NEC mean age 
(years) 
Stomach 64.3 56.1 73.6 
Small intestine 54.6 54.6 * 
Appendix 28.7 28.7 * 
Colon 61.2 58.8 67.5 
Rectum 59.8 58.7 65.0 
* no cases occurred at these anatomic sites
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3.3 Gender 
Information on the patients’ gender was provided on the hospital sticker as self-identified 
by the patient.  This information was captured in the electronic database and was 
available for all cases (Table 8). 
Table 8: Comparison of gender between tumour groups 
All cases WD NET PD NEC 
Male (%) 34 (49%) 27 (49%) 7 (50%) 
Female (%) 35 (51%) 28 (51%) 7 (50%) 
Total cases 69 55 14 
Fisher’s exact test p = 1.00 
There was no gender predilection demonstrated in either the WD NET or the PD NET 
groups.  Table 9 shows the number of male and female cases grouped by anatomic site. 
Table 9: Gender composition of NENs grouped by anatomic site 
Male Female 
Stomach 8 (53%) 7 (47%) 
Small intestine 6 (38%) 10 (62%) 
Appendix 4 (57%) 3 (43%) 
Colon 7 (50%) 7 (50%) 
Rectum 9 (53%) 8 (47%) 
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3.4 Type of sample 
The type of specimen (excision or biopsy) was available from the original histology report 
and confirmed by examination of the glass slides (Table 10).  PD NECs were more likely to 
be found in biopsy cases than WD NETs, which were the more common tumour type in 
the excision cases (p <0.002). 
Table 10: Comparison of specimen type (biopsy/excision) and NEN group 
All cases WD NET PD NEC 
Excision (%) 41 (59%) 38 (69%) 3 (21%) 
Biopsy (%) 28 (41%) 17 (31%) 11 (79%) 
Total cases 69 55 14 
Fisher’s exact test p < 0.002 
3.5 Site of tumour 
The sites of the tumours were available from the original histology reports and this data is 
summarised in the pie chart (Figure 2).  Of note, we were only able to include 7 cases 
from the appendix.  This is due to the irretrievability of some wax blocks and the small 
volume of tumour present in appendiceal WD NETs. 
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Figure 2: Proportion of study cases illustrated according to anatomical site
3.6 Grading 
Ki-67 immunohistochemistry was evaluated on all 69 cases.  The technique used is 
demonstrated in Figure 3.  Two of the 69 cases were unsuitable for evaluation of mitotic 
count due to smearing artefact.  Both of these cases were poorly differentiated 
neuroendocrine carcinomas, one from the rectum and one from the stomach.  Based on 
the tumour morphology, mitotic count, and Ki-67 proliferative index there were 14 cases 
(20%) classified as PD NEC and 55 (80%) classified as WD NET (Table 11).  Examples of 
cases that were classified as WD NET and PD NEC are shown in Figures 4 to 8. 
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NEN_07 176/376 = 46.8% 
NEN_19 17/385 = 4.4% 
Figure 3: Examples of Ki-67 manual counting technique (400x magnification) 
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Table 11: Number of tumours graded according to 2019 WHO classification system 
Well differentiated NET 
  Grade 1 38 (55%) 
  Grade 2 16 (23%) 
  Grade 3 1 (1.5%) 
Poorly differentiated NEC 
  Small cell-type 13 (19%) 
  Large cell-type 1 (1.5%) 
Figure 4: WD NET (NEN_03) low magnification showing insular growth (H&E, 40x) 
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Figure 5: WD NET (NEN_03) high magnification showing round nuclei with stippled 
chromatin (H&E, 400x) 
Figure 6: PD NEC small cell type (NEN_02) showing sheets of tumour cells, intermediate 
magnification (H&E, 100x) 
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Figure 7: PD NEC small cell type (NEN_02) showing round to polyhedral cells with scanty 
cytoplasm and high nuclear-to-cytoplasmic ratios, high magnification (H&E, 400x) 
Figure 8: PD NEC large cell type (NEN_45) showing medium sized cells with basophilic 
cytoplasm and large ovoid nuclei, high magnification (H&E, 400x)
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The PD NECs had a mean mitotic count of 16.1 per 2mm2 (range 0.5-43).  The mean Ki-67 
index for these tumours was 66.5% (range 32-100%).  The WD NETs had a mean mitotic 
count of 0.4 per 2mm2 (range 0- 2.2) and a median Ki-67 index of 2.0% (mean 3.7%; range 
0-64%).  The skewed Ki-67 index mean value is due to the single grade 3 WD NET which
demonstrated a Ki-67 proliferative index of 64.1%. 
The PD NECs occurred in the stomach and colorectum, and none were found in the small 
intestine and appendix.  All of the tumours in the small intestine and appendix were WD 
NETs (grade 1 or 2).  There was a single grade 3 WD NET identified in the colon (Figures 9 
and 10).  This tumour demonstrated a mitotic rate of 1 per 2mm2 and had a Ki-67 
proliferation index of 64%.  The breakdown of tumour grades at the different anatomic 
sites is shown in Table 12. 
Figure 9: WD NET grade 3 (NEN_32) showing nests of tumour cells underlying a mucosal 
ulcer, intermediate magnification (H&E, 100x)
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Figure 10: WD NET grade 3 (NEN_32) showing tumour cells with moderate eosinophilic 
cytoplasm and nuclei with stippled chromatin, high magnification (H&E, 400x)
Table 12: Comparison of the NEN grades found at different anatomical sites 
WD NET PD NEC 






Stomach 5 3 0 7 0 15 (22%) 
Small 
intestine 
10 6 0 0 0 16 (23%) 
Appendix 6 1 0 0 0 7 (10%) 
Colon 8 1 1 3 1 14 (20%) 
Rectum 9 5 0 3 0 17 (25%) 




INSM1 immunohistochemistry was performed on all 69 cases and the 17 control cases.  
Figure 11 shows the various staining intensities.  Fifty-five of the 69 cases (80%) showed 
positive staining with INSM1 (Table 13).  The single grade 3 WD NET was negative for 
INSM1 (not shown in Table 13).  None of the 17 control cases met our H-score criteria for 
positivity with INSM1.  There were however isolated positive cells which showed 
neuroendocrine differentiation in all of the adenocarcinoma cases.  The colonic 
adenocarcinoma case which was positive for synaptophysin according to our H-score 
criteria, had an INSM1 H-score of 25.  
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Positive control (PanNET) 1+ 
2+ 3+ 
Figure 11: Staining intensities of INSM1 (400x magnification)
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Table 13: INSM1 staining stratified by tumour grade and anatomic site 
INSM1 
Positive Negative p* 
Tumor Grade .919 





































INSM1 staining was not significantly different between WD and PD NENs (p = 0.919).  
There was no significant difference between the WD NET grades.  The single grade 3 NET 
was negative for INSM1.  A high proportion of tumours in the stomach, colorectum and 
appendix showed positive staining (80-100%).  Only 56% of small intestine tumours were 
positive, but this finding was not statistically significant (p = 0.058).  
3.7.2 Synaptophysin 
Synaptophysin immunohistochemistry was performed on all 69 cases and 17 controls.  
Sixty of the 69 cases (87%) showed positive staining with synaptophysin.  Figure 12 shows 
examples of the synaptophysin staining intensities.  The grade 3 WD NET case was 
positive for synaptophysin (not shown in Table 14).  One of the 17 control cases (6%) 
showed positive staining.  This positive control case was a colonic adenocarcinoma with 
an H-score of 40 (intensity 1, proportion 40%).  
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Positive control (PanNET) 1+ 
2+ 3+ 
Figure 12: Staining intensities of synaptophysin (400x magnification)
Synaptophysin was less likely to be positive in the PD NECs as compared with the WD 
NETs (Table 14).  This difference was statistically significant (p = 0.012).  There was no 
significant difference in the proportion of positively staining cases when stratified by the 
anatomic site (p = 0.161). 
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Table 14: Synaptophysin staining stratified by tumour grade and anatomic site 
Synaptophysin 
Positive Negative p* 
Tumor Grade .012 





































3.7.3 Chromogranin A 
Chromogranin A immunohistochemistry was performed on all 69 cases and 17 controls.  
Forty-seven of the 69 cases (68%) were positive with chromogranin A.  The grade 3 WD 
NET was positive for chromogranin A (not shown in Table 15).  Examples of cases positive 
for chromogranin A are shown in Figure 13.  Two of the 17 control cases (12%) were 
positive with chromogranin A.  These represented one small bowel diffuse large B cell 
lymphoma (H-score = 30), and one gastric adenocarcinoma (H-score = 30). 
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Positive control (colon) 1+ 
2+ 3+ 
Figure 13: Staining intensities of chromogranin A (400x magnification) 
There was no statistically significant difference in chromogranin A positivity between the 
well differentiated NETs and poorly differentiated NECs (p = 0.318).  The proportion of 
colorectal cases which showed positive labelling with chromogranin A was significantly 
lower than at the other anatomic sites (p < 0.001) (Table 15). 
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Table 15: Chromogranin A staining stratified by tumour grade and anatomic site 
Chromogranin A 
Positive Negative p* 
Tumor Grade .318 





































3.8 Sensitivity and Specificity of Immunohistochemical Stains 
Twenty-eight cases showed positivity for all three neuroendocrine markers examined in 
this study (Table 16).  The majority of cases (54%) were positive for only 2 markers.  In the 
4 cases that were only identified by a single neuroendocrine immunohistochemical 
marker, INSM1 was the positive stain.  These cases were 3 small cell type PD NECs (2 cases 
from the rectum, 1 case from the stomach) and 1 grade 1 WD NET (rectum). 
Table 16: Cases positive for different numbers of immunohistochemical markers 
Immunohistochemical positivity Number of cases 
 All three NE markers 28 (41%) 
 Any two markers 37 (54%) 
 Any one marker 4 (5%) 
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The area under the curve (AUC) calculation demonstrates that the expression for all the 
stains (with the exception of chromogranin A in the PD NEC group) were better than 
chance (Table 17). 
Table 17: Sensitivities and specificities of IHC markers based on tumour type and grade 
AUC Std Error p 95% CI Sensitivity Specificity 
All cases 
 INSM1 0.899 0.033 <.001 0.84 - 0.96 79.7% 100% 
 CGA 0.782 0.058 <.001 0.67 - 0.90 68.1% 88.2% 
 SYNAP 0.905 0.041 <.001 0.83 - 0.99 87% 94.1% 
 CGA-SYNAP 0.883 0.057 <.001 0.77 - 0.99 94.2% 82.4% 
WD G1 NET 
 INSM1 0.908 0.040 <.001 0.83 – 0.99 81.6% 100% 
 CGA 0.796 0.064 .001 0.67 – 0.92 71.1% 88.2% 
 SYNAP 0.918 0.044 <.001 0.83 – 1.00 89.5% 94.1% 
 CGA-SYNAP 0.899 0.057 <.001 0.79 – 1.00 97.4% 82.4% 
WD G2 NET 
 INSM1 0.875 0.068 <.001 0.74 – 1.00 75% 100% 
 CGA 0.816 0.079 .002 0.61 – 0.97 75% 88.2% 
 SYNAP 0.971 0.034 <.001 0.90 – 1.00 100% 94.1% 
 CGA-SYNAP 0.912 0.057 <.001 0.80 – 1.00 100% 82.4% 
PD NEC 
 INSM1 0.893 0.069 <.001 0.76 – 1.00 78.6% 100% 
 CGA 0.691 0.099 .071 0.50 – 0.89 50% 88.2% 
 SYNAP 0.792 0.088 .006 0.62 – 0.97 64.3% 94.1% 
 CGA-SYNAP 0.810 0.084 .004 0.64 – 0.97 78.6% 82.4% 
AUC= area under curve 
Overall INSM1 had a sensitivity of 79.8% and specificity of 100%.  The sensitivity of INSM1 
was higher than chromogranin A, but lower than synaptophysin and the combined use of 
chromogranin A and synaptophysin (Figure 14).   
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Figure 14: ROC curve considering all cases of NEN
When only considering cases of PD NEC, INSM1 had a higher sensitivity than 
chromogranin A and synaptophysin, and an equal sensitivity to the combined use of 
chromogranin A and synaptophysin (Figure 15).  The use of chromogranin A in isolation 
for PD NEC was statistically no better than chance (p=.071). 
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Figure 15: ROC curve considering only PD NEC cases
Synaptophysin alone and the combined use of synaptophysin and chromogranin A 
demonstrated a higher sensitivity than INSM1 when considering only WD NETs (Figures 16 
and 17).  INSM1 had a higher sensitivity than chromogranin A when considering only WD 
NET cases.  
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Figure 16: ROC curve evaluating only the grade 1 WD NET cases 




The mean patient age in this study was 56.7 years (range 14-85).  Cases of PD NECs were 
on average older (mean 70 years) than patients with WD NETs (mean 53.4 years) and this 
result was found to be statistically significant.  Comparing the mean age of NEN cases by 
anatomic site showed appendix 28.7 years, small intestine 54.6 years, rectum 59.8 years, 
colon 61.2 years and stomach 64.3 years.  This is very similar to what is quoted in the 
international literature.(2, 9, 14, 15) 
4.2 Gender 
In our study we had an almost even proportion of males (n=34; 49%) and females (n=35; 
51%).   This is in keeping with the international literature which reports no gender 
predilection.(2)  When examining cases stratified by anatomic site, a higher proportion of 
small intestine cases were female (n=10; 62%) compared with male cases (n=6; 38%).  This 
is different to what is reported in the literature.  A large study examining 14850 
appendicectomy cases in the United Kingdom found appendiceal NETs to have a female 
predominance of 60.5%.(15)  We found the opposite trend with only 43% female cases of 
appendiceal NENs.  This discordance may be due to selection bias and our small sample 
size, as we only had 7 appendixes in our study. 
4.3 Type of sample 
Most of our cases (59%) were excision specimens.  Of the 41 excision specimens 38 (93%) 
were WD NETs.  This result is expected as PD NECs are more likely to have a higher clinical 
stage at presentation and may not be amenable to surgical intervention.  PD NECs also 
generally occur in older individuals who may have medical comorbidities contraindicating 
surgery.  Of the 28 biopsy specimens 11 were PD NECs (40%). 
46 
4.4 Site of tumour 
Our aim was to retrieve 25 cases from each of the 5 anatomic sites identified.  We were 
able to retrieve and include 17 cases (25%) from the rectum, 16 (23%) from the small 
intestine, 15 (22%) from the stomach, 14 (20%) from the colon, and 7 (10%) from the 
appendix.  The proportion of cases from the appendix was lower than intended.  This 
occurred because most appendiceal NENs are microscopic and so there was insufficient 
tissue remaining for further immunohistochemical stains. 
4.5 Grading 
The majority of WD NETs in our study were grade 1 (69%), followed in proportion by 
grade 2 (29%), with only one grade 3 tumour (1.5%) identified.  The proportion of grade 3 
WD NETs in our series is lower than that found in other studies.  Gonzalez et al reported 
22% of the NEN cases in their study as grade 3 NETs.(3)  Their study did however include 
pancreatic NENs but they do not specify how many of these grade 3 NETs occurred in the 
pancreas.  Fourteen out of our 69 cases (20%) were classified as PD NEC.  Only one case of 
PD NEC was classified as large cell NEC.  This finding confirms the rarity of large cell NEC 
which is described in the literature.(2) 
There were no PD NECs identified in the small intestine or appendix.  This supports the 
international literature in which only isolated case reports have been published of 
appendiceal PD NECs.(46)  Jejunoileal PD NECs are similarly extremely rare.(47)  In the 
small intestine, PD NECs occur almost exclusively at the duodenal ampulla.  We did not 
have any cases of duodenal NENs which explains why no small intestinal PD NECs were 
identified. 
The PD NECs in our study were evenly split between the stomach (50%) and colorectum 
(50%).  Stomach PD NECs are reported to comprise 20.5% of all GI PD NECs.(13)  There 
was a higher proportion in our study.  This may be due to selection bias and the small 
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sample size.  The colorectum is the most common site for GI PD NEC reported in the 
literature.(11)  This was supported by our data. 
4.6 Immunohistochemistry 
4.6.1 INSM1 
We found a sensitivity of 79.7% for INSM1 immunohistochemistry with 55 out of 69 cases 
showing positive staining.  This result is lower than reported in the literature.  González et 
al found a sensitivity of 100% in their study examining 30 GI NEN cases.(3)  This study had 
a small sample size, only one case of PD NEC and it is uncertain what cut off they used for 
intensity and proportion in assigning positivity.  Our sensitivity result is also lower than 
those reported for NENs at other anatomic sites in the literature.(32, 33)  Thoracic NENs, 
head and neck NENs and Merkel cell carcinomas are high-grade with small cell 
morphology.  The high proportion of low-grade NETs in our study may account for this 
discrepancy.  In addition, we noted that the immunoreactivity on some of our older cases 
(pre 2010) was not strong and perhaps poor preservation of the wax blocks led to 
decreased antigenicity in these cases. 
The specificity of INSM1 was 100% with none of our 17 control cases showing positive 
immunohistochemical labelling.  The study reported by González et al found positive 
staining in colorectal adenocarcinoma, adrenal cortical carcinoma, solid pseudopapillary 
neoplasm of the pancreas and breast carcinoma.(3)  They used lower cut off values to 
define positivity, accepting a proportion of only 5% expression as positive.  Our smaller 
number of controls and higher cut off value for assigning positivity may account for our 
higher specificity. 
Stratification of INSM1 staining by tumour grade revealed the highest sensitivity in the PD 
NEC group (85.7%), followed by grade 1 WD NET (81.6%) and grade 2 WD NET (75%).  The 
single case of grade 3 WD NET was negative for INSM1.  These differences were not 
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statistically significant (p = 0.919).  Our results were all lower than those reported by 
González et al as they found sensitivities of 100% in all groups.(3) 
INSM1 showed high sensitivity in the appendix (100%), colorectum (87.1%) and stomach 
(80%).  The sensitivity was only 56.3% in the small intestine.  The reason for this is 
uncertain, particularly since synaptophysin and chromogranin A were very sensitive in the 
small intestine.  There was a high proportion of low-grade WD NETs in the small intestine 
and this may have contributed to these results. 
4.6.2 Synaptophysin 
The sensitivity of synaptophysin was 87% (60 out of 69 cases stained positively) and the 
specificity was 94% (1 out of 17 controls positive).  The positive control case was an 
adenocarcinoma of the colon.  Neuroendocrine differentiation in GI adenocarcinomas is 
well described in the literature.  The sensitivity of synaptophysin in our study is lower than 
that reported in the literature.  The study by Gonzalez et al found synaptophysin to have a 
sensitivity of 100% in their series of 32 gastroenteropancreatic NENs.(3)   
We found that synaptophysin was less likely to stain PD NEC (sensitivity 64.3%) than WD 
NET (sensitivity 93%).  This difference in sensitivity was not found in the study by Gonzalez 
et al.(3)  
Synaptophysin stained 80% of the gastric NENs which is higher than the rate reported in 
the literature of 50%.(18, 22) 
4.6.3 Chromogranin A 
The sensitivity of chromogranin A in our study was 68% (47 out of 69 cases showing 
positive staining).  The specificity was 88% with 2 of the 17 controls staining positively.  
One of these positive controls was a diffuse large B-cell lymphoma of the small intestine. 
The staining in this case was weak and patchy and best interpreted as aberrant (even 
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though it did meet the threshold criteria for positivity with an H-score of 30).  
Chromogranin A labelling of lymphomas has not been reported in the literature.  
The sensitivity of chromogranin A in our study is lower than that reported by González et 
al who found an overall sensitivity of 97%.  There was no statistically significant difference 
when positive staining was examined by tumour grade.   
Chromogranin A had a low sensitivity in the colorectum, staining only 41.9% of cases (p = 
.001).  This phenomenon is well described in the literature and has to do the cell of origin 
of the NEN.(41) 
4.7 Comparison of INSM1, Synaptophysin and Chromogranin A 
Considering all GI NEN cases in this study, INSM1 had a sensitivity (79.7%) that was higher 
than chromogranin A (68.1%), but lower than synaptophysin (87%) and the combined use 
of synaptophysin and chromogranin A (94.2%).  The combined use of synaptophysin and 
chromogranin A detected more cases than the use of only INSM1, but this difference was 
not statistically significant.  The study by Gonzales et al quoted a better sensitivity for 
INSM1 but they did not report on statistical significance, possibly due to a small sample 
size.  When considering data on NENs at other anatomical sites, our results are different 
to the findings of Rooper et al who described a sensitivity of INSM1 of 96.4% across all 
grades of thoracic NENs which was significantly more than the sensitivity of 87.4% 
achieved by a panel of synaptophysin, chromogranin A and CD56.(31) 
Analyzing only the PD NEC cases showed that INSM1 (0.893) had a higher area under the 
curve (AUC) than chromogranin A (0.691), synaptophysin (0.796), and the combined use 
of synaptophysin and chromogranin A (0.810).  This result was statistically significant.   
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Comparing the sensitivities and specificities of the three immunohistochemical markers in 
the WD NET group revealed no statistically significant difference between the use of 
INSM1 alone and the combined use of synaptophysin and chromogranin A. 
It is interesting to note that of the 4 cases which were negative for both synaptophysin 
and chromogranin A, the INSM1 stain was positive. 
4.8 Study design 
Our study included both resection and biopsy specimens.  We only included cases with 
sufficient tumour to accurately assess mitotic count and Ki-67 proliferative index 
according to the international guidelines.  This was not possible on many of the biopsy 
specimens and in many appendicectomy specimens.  Excluding these cases may have 
introduced selection bias. 
We were able to identify a sufficient number of cases by searching the laboratory 
electronic information systems (DISA and Trakcare).  Obtaining the wax blocks from our 
archives was a challenge for various logistical reasons and many cases were irretrievable.  
If time permitted, we would have reselected more cases and attempted to retrieve their 
wax blocks.  However, we had already requested all the resection specimens, and had we 
requested additional biopsy specimens it is likely that many of them would also have had 
insufficient remaining tissue for analysis. 
There was only one grade 3 WD NET in this study.  It is uncertain why the incidence of 
grade 3 WD NET was so low in our population. 
Several pre-analytical factors could have influenced the outcomes of this study.  These 
include tissue fixation and preservation of tissue in the wax blocks.  Underfixation has a 
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negative impact on antigen retrieval and can result in false negative 
immunohistochemical stains.(48) 
The dilutions of the primary antibodies used in this study were optimized prior to 
beginning the study.  The staining protocol was standardized and carried out in batches. 
Positive and negative external controls were used for each batch.  Positive internal 
controls were also identified where applicable. 
All slides were coded to reduce bias.  Intra-observer variability was reduced by scoring the 
immunohistochemical stains by the same pathologist, using the same microscope, in as 
few sittings as possible.  Scoring of the INSM1 immunohistochemical stains and the 
synaptophysin and chromogranin A stains was checked by the supervising pathologist. 
Future studies should include a larger sample size to achieve statistical significance.  
Multicentre collaboration would be of value as these tumours are uncommon and it is 
difficult to find sufficient suitable cases at a single centre.   
The low sensitivity of INSM1 in small bowel WD NETs found in our study is of interest and 
should be investigated further and at different centres. 
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5. CONCLUSIONS
1. GI NENs are tumours of middle-aged adults and PD NECs occur in older individuals,
findings consistent with international data.
2. Within the WD NET group, grade 1 tumours comprise the majority (69%) of cases,
grade 2 tumours make up 29% and grade 3 tumours only 2%.
3. There is a very low prevalence of grade 3 WD NETs in our study sample.
4. PD NECs occurred only in the stomach and colorectum in this study.
5. Chromogranin A stained significantly fewer colorectal NENs, a result supported by
the literature.
6. Synaptophysin stained the majority of gastric NENs, more than reported in the
literature.
7. Although INSM1 stained fewer overall tumours than did the combined use of
synaptophysin and chromogranin A, this difference is not statistically significant.
8. INSM1 stained fewer small bowel NENs than synaptophysin in our study, although
this finding was not statistically significant.
9. INSM1 has equivalent sensitivity to the combined use of synaptophysin and
chromogranin A in PD NECs and a higher specificity, making it a more robust
marker in this setting.
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6. APPENDICES
Appendix 1: Summary of cases 




NEN_01 58 F E Stomach WD NET G1 
NEN_02 51 F E Colon NEC, small cell 
NEN_03 70 M E Small intestine WD NET G1 
NEN_04 18 F E Appendix WD NET G1 
NEN_05 33 F E Appendix WD NET G1 
NEN_06 72 M B Stomach WD NET G2 
NEN_07 62 M B Rectum NEC, small cell 
NEN_08 49 M B Rectum WD NET G1 
NEN_09 37 M E Stomach WD NET G1 
NEN_10 18 F E Appendix WD NET G1 
NEN_11 52 M E Appendix WD NET G1 
NEN_12 46 F E Small intestine WD NET G1 
NEN_13 60 M E Small intestine WD NET G1 
NEN_14 55 M B Stomach WD NET G1 
NEN_15 51 F E Small intestine WD NET G1 
NEN_16 32 F E Small intestine WD NET G1 
NEN_17 76 F B Rectum WD NET G2 
NEN_18 65 M E Small intestine WD NET G2 
NEN_19 14 M E Appendix WD NET G2 
NEN_20 82 M B Stomach NEC, small cell 
NEN_21 51 M E Rectum WD NET G1 
NEN_22 34 F E Small intestine WD NET G2 
NEN_23 54 M E Small intestine WD NET G1 
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NEN_24 62 M E Small intestine WD NET G2 
NEN_25 21 M E Appendix WD NET G1 
NEN_26 46 F B Rectum WD NET G1 
NEN_27 69 F B Stomach NEC, small cell 
NEN_28 51 F E Small intestine WD NET G2 
NEN_29 68 M B Rectum NEC, small cell 
NEN_30 65 F E Stomach NEC, small cell 
NEN_31 77 M B Stomach NEC, small cell 
NEN_32 42 M B Colon WD NET G3 
NEN_33 55 F B Colon WD NET G2 
NEN_34 43 M B Stomach WD NET G2 
NEN_35 58 F E Small intestine WD NET G1 
NEN_36 60 M B Rectum WD NET G2 
NEN_37 70 F B Rectum WD NET G2 
NEN_38 57 F B Rectum WD NET G2 
NEN_39 49 M B Rectum WD NET G1 
NEN_40 53 F E Small intestine WD NET G2 
NEN_41 57 M E Colon WD NET G1 
NEN_42 66 F B Stomach WD NET G1 
NEN_43 68 F B Stomach NEC, small cell 
NEN_44 61 M E Colon WD NET G1 
NEN_45 77 M B Colon NEC, large cell 
NEN_46 64 M E Rectum WD NET G1 
NEN_47 69 F E Rectum WD NET G1 
NEN_48 70 F B Stomach NEC, small cell 
NEN_49 45 M E Appendix WD NET G1 
NEN_50 46 F E Stomach WD NET G2 
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NEN_51 55 F E Small intestine WD NET G1 
NEN_52 76 F B Rectum WD NET G1 
NEN_53 72 M E Stomach WD NET G1 
NEN_54 60 F E Colon WD NET G1 
NEN_55 57 F E Colon NEC, small cell 
NEN_56 70 M B Rectum WD NET G1 
NEN_57 63 F E Small intestine WD NET G2 
NEN_58 60 M B Colon WD NET G1 
NEN_59 70 M E Small intestine WD NET G1 
NEN_60 52 F B Colon WD NET G1 
NEN_61 48 F E Rectum WD NET G1 
NEN_62 70 M E Colon WD NET G1 
NEN_63 66 F E Colon WD NET G1 
NEN_64 50 F E Small intestine WD NET G1 
NEN_65 65 M B Rectum NEC, small cell 
NEN_66 65 M E Colon WD NET G1 
NEN_67 85 F B Colon NEC, small cell 
NEN_68 84 M B Stomach NEC, small cell 
NEN_69 37 F E Rectum WD NET G2 
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